Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lakshmikant, Gupta"'
Autor:
Krishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, Ankit Patel, Kinjal Thakkar, Dinesh Patel, Manoranjan Sharma, Jaideep Singh, Jogeswar Mohapatra, Abhijit Chatterjee, Dipam Patel, Rajesh Bahekar, Rajiv Sharma, Lakshmikant Gupta, Nirmal Patel, Poonam Giri, Nuggehally R. Srinivas, Mukul Jain, Debdutta Bandyopadhyay, Pankaj R. Patel, Ranjit C. Desai
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhi
Externí odkaz:
https://doaj.org/article/426ccabb23744fc0aceb0a7d29b505f0
Autor:
Dinesh Patel, Dipam Patel, Pankaj R. Patel, Jogeswar Mohapatra, Hoshang Patel, Krishnarup Ghoshdastidar, Abhijit Chatterjee, Rajiv P. Sharma, Mukul R. Jain, Jaideep Singh, Manoranjan Sharma, Poonam Giri, Kinjal Thakkar, Debdutta Bandyopadhyay, Rajesh Bahekar, Hitesh Bhayani, Ranjit C. Desai, Ankit Patel, Lakshmikant Gupta, Nuggehally R. Srinivas, Nirmal Patel
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4e4ffa841ea0712306327b9f3c7fca
https://doaj.org/article/426ccabb23744fc0aceb0a7d29b505f0
https://doaj.org/article/426ccabb23744fc0aceb0a7d29b505f0
Autor:
Poonam Giri, Vipul Joshi, Nuggehally R. Srinivas, Nirmal Patel, Lakshmikant Gupta, Sneha Naidu, Shyamkumar Giri
Publikováno v:
Drug Metabolism Letters
Background: The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process. Although many drugs can be metabolized to sulfoxide and/or sul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba06a82dc926740e2398b2ecb90ff045
https://doi.org/10.2174/1872312812666180816164626
https://doi.org/10.2174/1872312812666180816164626
Autor:
Poonam Giri, Pankaj R. Patel, Nuggehally R. Srinivas, Nirmal Patel, Sanjay Singh, Lakshmikant Gupta, Brijesh Kumar Srivastva, Ranjit C. Desai
ZYTP1 is a novel Poly (ADP-ribose) polymerase protein inhibitor being developed for cancer indications.The focus of the work was to determine if ZYTP1 had a perpetrator role in the in vitro inhibition of cytochrome P450 (CYP) enzymes to aid dosing de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8967d09aa80d6f1df49f4019e85af5a8
Autor:
Poonam, Giri, Lakshmikant, Gupta, Sanjay, Singh, Nirmal, Patel, Nuggehally R, Srinivas, Brijesh Kumar, Srivastva, Ranjit C, Desai, Pankaj R, Patel
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(10)
ZYTP1 is a novel Poly (ADP-ribose) polymerase protein inhibitor being developed for cancer indications. The focus of the work was to determine if ZYTP1 had a perpetrator role in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::83791720c48bb2e3e8b6e80c0712373c
https://pubmed.ncbi.nlm.nih.gov/30488748
https://pubmed.ncbi.nlm.nih.gov/30488748
Autor:
Prashant Delvadia, Poonam Giri, Namrata Prajapati, Vipul Joshi, Shyamkumar Giri, Pankaj R. Patel, Mukul R. Jain, Nuggehally R. Srinivas, Meera K. Ladani, Nirmal Patel, Lakshmikant Gupta
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 130
Saroglitazar, a PPAR αҮ agonist, is currently undergoing global development for the treatment of NASH and other indications. Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM). The aim was to carry out drug-drug interac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fff7701d6d680698ff0fe118f5516d
https://pubmed.ncbi.nlm.nih.gov/30633968
https://pubmed.ncbi.nlm.nih.gov/30633968
Autor:
Jaideep Singh, Poonam Giri, Lakshmikant Gupta, Priyal Trivedi, Prashant Delvadia, Manoranjan Sharma, Abhijit Chatterjee, Nuggehally R. Srinivas, Nirmal Patel, Shekhar Kadam
Pharmacokinetics of voriconazole, an anti-fungal agent, was determined in collagen-induced arthritic (CIA) and healthy DBA/1J mice. CIA was confirmed in DBA/1J mice by clinical scoring and histological analysis.In vivo oral pharmacokinetic study (3 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c94a2af68dcf6a2dcdd5a33415c2a8a0
Autor:
Giri, Poonam1 (AUTHOR) poonamgiri@zyduscadila.com, Gupta, Lakshmikant1 (AUTHOR), Singh, Sanjay1 (AUTHOR), Patel, Nirmal1 (AUTHOR), Srinivas, Nuggehally R.1 (AUTHOR), Srivastva, Brijesh Kumar2 (AUTHOR), Desai, Ranjit C.2 (AUTHOR), Patel, Pankaj R.3 (AUTHOR)
Publikováno v:
Xenobiotica. Oct2019, Vol. 49 Issue 10, p1164-1172. 9p.
Autor:
Giri, Poonam1, Delvadia, Prashant1, Gupta, Lakshmikant1, Trivedi, Priyal1, Patel, Nirmal1, Srinivas, Nuggehally R.1, Sharma, Manoranjan2, Singh, Jaideep2, Chatterjee, Abhijit2, Kadam, Shekhar3
Publikováno v:
Xenobiotica. Jun2019, Vol. 49 Issue 6, p698-707. 10p.